ErbB2 _ HER2 Antibody
- Known as:
- ErbB2 _ HER2 Antibody
- Catalog number:
- 10004-MM01
- Product Quantity:
- 100
- Category:
- -
- Supplier:
- Smart Serology
- Gene target:
- ErbB2 _ HER2 Antibody
Related genes to: ErbB2 _ HER2 Antibody
- Gene:
- ERBB2 NIH gene
- Name:
- erb-b2 receptor tyrosine kinase 2
- Previous symbol:
- NGL
- Synonyms:
- NEU, HER-2, CD340, HER2
- Chromosome:
- 17q12
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2019-04-23
Related products to: ErbB2 _ HER2 Antibody
Related articles to: ErbB2 _ HER2 Antibody
- Salivary duct carcinoma (SDC) is a rare and aggressive malignancy of the salivary glands, most commonly originating in the parotid gland and less frequently in the submandibular gland. Isolated axillary lymph node metastasis is extremely uncommon, and its clinical characteristics and optimal management remain unclear. - Source: PubMed
Publication date: 2026/05/20
Zhu NingZhao GuileHan QiHua YufeiWang GuanruBao MingzheGao NingLi Chunjie - With recent approvals of multiple targeted therapies for triple-negative breast cancer (TNBC), including antibody-drug conjugates and immunotherapy in biomarker-selected populations, it is critical to define the temporal evolution of cell-surface target expression from early-stage to metastatic disease, the co-expression patterns across these markers, and optimal quantification methodologies. Here we report biomarker expression profiles measured by multi-omics and pathology-based platforms in patients with TNBC using a large cohort of matched longitudinal tumor samples. - Source: PubMed
Publication date: 2026/05/25
Gomez Tejeda Zanudo JorgeBinboga Kurt BusemFrangieh AllisonBarkell Alice MNavarro JohnNgo LanMohammed-Abreu AyeshaPrade Verena MBisha InaAbhishek SudhanshuKim Beom-JunHughes MelissaHelvie Karla EBaginska JoannaClark David JSchick MarkusHill Ross JKing Tari AMittendorf Elizabeth ARebelatto MarlonWiner Eric PTolaney Sara MJohnson Bruce ECarroll DanielleScaltriti MaurizioLin Nancy Ude Bruin Elza CGarrido-Castro Ana C - Transplantation of adipose-derived mesenchymal stromal cells (ASCs) or their insulin-producing derivatives holds promise for diabetes mellitus therapy due to their regenerative properties. However, the harsh microenvironment in type 2 diabetes (T2D) likely impairs autologous ASC efficacy. - Source: PubMed
Publication date: 2026/06/04
Zeinhom AlaaMohamed Ammar YAbdel-Aziz Nahla NSayed Diab MostafaSalem Amir M HYassen Noha NMohammed Eman E AMohamed Amal MEid Ola MHussein Shymaa HFarid MarwaTharwat Engy KAli Kholoud AElmeligy Hesham AFadallah Sahar AAzmy OsamaAbu-Shahba NourhanMahmoud Marwa - Trastuzumab emtansine (T-DM1) is the standard adjuvant treatment for HER2-positive breast cancer with residual disease after neoadjuvant chemotherapy. Its concurrent use with locoregional radiation therapy (RT) is increasingly common, yet data on pulmonary safety remain scarce. - Source: PubMed
Publication date: 2026/06/04
Beddok ArnaudGirres LauraTorielli PaoloVigneau EstelleEttalhaoui LeilaHotton JudicaelJouannaud ChristelleMazza CamilleLemoine AmélieParent DamienRoque AlexandreSoibinet PaulineVignot StéphaneMerrouche YacineGuilbert Philippe - Background Few models exist for studying experimental therapeutics in inflammatory breast cancer (IBC). Our study objective was to characterize a novel patient-derived xenograft (PDX) from a HER2 positive IBC patient refractory to neoadjuvant chemotherapy. Methods We derived a novel PDX from a patient with hormone receptor negative, HER2-positive IBC refractory to neoadjuvant chemotherapy with Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP). Tumor was implanted into NOD/SCID/γ mice (NSG) and used for serial propagation of PDX. We performed short-tandem repeat (STR) profiling, plotted tumor growth curves for mice treated with alpelisib/everolimus vs. untreated, and immunohistochemistry (IHC), and performed clinical genomic assays. Paired Student's t-tests were used to compare tumor growth curves. We used 10X Genomics for single cell transcriptome analysis of 1000 cells derived from the PDX. Results ctDNA sequencing revealed amplifications in MYC, ERBB2 (HER2), androgen receptor (AR), PIK3CA, vMYB and loss of CDKN2A. Tumor sequencing found a H1047R mutation in PIK3CA. STR profiling showed the propagated PDX tumor matched the original tumor. The engraftment rate was 12/15 (80%) and median tumor volume doubling was 24.5 days (range 9.2-175 days) for n = 15 untreated controls. Alpelisib plus everolimus decreased tumor growth in our PDX (p = 0.006). TCHP-resistant tumor cells downregulated HER2 expression, which was re-expressed after treatment with alpelisib and everolimus. Conclusion We established a PDX of a HER2-positive IBC tumor with a PIK3CA hotspot mutation (H1047R) refractory to TCHP. Targeting the PI3K/mTOR pathway may be useful to overcome resistance in HER2-positive IBC with a H1047R mutation in PIK3CA. - Source: PubMed
Publication date: 2026/05/18
Ekpo PrincessKhattak MonicaCheung TiffanySu Yun YunBains Pushpinder KJuric IvanMakarov VladimirCampo DanielMcIntire PatrickRing AlexanderKrings GregorList KarinHicks JamesPress Michael FKeri RuthStanczyk MichaelSengupta GigiLang Julie E